Zykadia

(Ceritinib)

Zykadia

Drug updated on 11/13/2023

Dosage FormTablet (oral:150 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

Product Monograph / Prescribing Information

Document TitleYearSource
Zykadia (ceritinib) Prescribing Information.2021Novartis Pharmaceuticals Corporation, East Hanover, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.2023Cancer
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non‑small cell lung cancer: a systematic review and meta‑analysis.2022Investigational New Drugs
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer. 2022Cochrane Database of Systematic Reviews
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis.2022Investigational New Drugs
Therapy for stage iv non–small-cell lung cancer with driver alterations: asco living guideline.2022Journal of Clinical Oncology
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials. 2021BMC Cancer
Efficacy and safety of ceritinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer: a systematic review and meta-analysis2020Journal of Clinical Pharmacy and Therapeutics
ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.2020PLOS ONE
The incidence of ALK inhibitor-related pneumonitis in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.2019Lung Cancer
Safety issues with the ALK inhibitors in the treatment of NSCLC: a systematic review.2019Critical Reviews in Oncology/Hematology
Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer.2019Medicine
Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.2018Oncotarget
Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.2018Oncotarget
Ceritinib alone for crizotinib-naive versus crizotinib-pretreated for management of anaplastic lymphoma kinase-rearrangement non-small-cell lung cancer: a systematic review.2018Clinical Lung Cancer
ALK inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis.2018PLoS One
Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer.2018Future Oncology

Clinical Practice Guidelines